Although we cannot accurately predict whether a cancer will respond to mJX-594 therapeutically based on their tumor immune profiles before treatment, we know that mJX-594 treatment markedly increases intratumoral CD3+ T cells and (more profoundly) CD8+ T cells, and simultaneously decreases immunosuppressive cells such as MDSCs and macrophages in the TME. The gene discussed is CD8A; the disease is neoplasm.